INT49866

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1995
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 53
Total Number 57
Disease Relevance 35.37
Pain Relevance 8.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (Parp1) nuclear envelope (Parp1) nucleolus (Parp1)
nucleus (Parp1) protein complex (Parp1) transcription factor binding (Parp1)
Anatomy Link Frequency
poly 6
lung 3
liver 2
NS20Y 2
brain 1
Parp1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 340 99.88 Very High Very High Very High
mu opioid receptor 26 99.56 Very High Very High Very High
Paracetamol 38 98.48 Very High Very High Very High
antagonist 1 97.42 Very High Very High Very High
diabetic neuropathy 6 96.76 Very High Very High Very High
cytokine 126 96.72 Very High Very High Very High
Morphine 13 96.72 Very High Very High Very High
Multiple sclerosis 62 96.36 Very High Very High Very High
cINOD 3 94.56 High High
Inflammatory mediators 33 92.40 High High
Disease Link Frequency Relevance Heat
Sepsis 150 100.00 Very High Very High Very High
Stress 111 100.00 Very High Very High Very High
Targeted Disruption 32 100.00 Very High Very High Very High
Toxicity 71 99.98 Very High Very High Very High
Urological Neuroanatomy 99 99.96 Very High Very High Very High
Death 96 99.92 Very High Very High Very High
INFLAMMATION 390 99.88 Very High Very High Very High
Ovarian Cancer 250 99.88 Very High Very High Very High
Cancer 311 99.60 Very High Very High Very High
Lung Injury 927 99.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To gain insight about the increased basal ATM-kinase activity after the inhibition of PARP-1 with ANI (figure 2C), we performed an indirect inmunofluorescence against H2AX in its phosphorylated form, after the incubation with the PARP inhibitor in order to detect any DNA damage response.
Negative_regulation (inhibition) of PARP-1
1) Confidence 0.58 Published 2007 Journal BMC Mol Biol Section Body Doc Link PMC1868035 Disease Relevance 0.07 Pain Relevance 0
PARP inhibitors promote ATM activation through induction of DSBs
Negative_regulation (inhibitors) of PARP
2) Confidence 0.58 Published 2007 Journal BMC Mol Biol Section Body Doc Link PMC1868035 Disease Relevance 0.08 Pain Relevance 0
The second main conclusion in this study is that inhibition of PARP-1 activity leads to DSBs induction and activation of ATM and, at the same time, prevents IR-induced ATM-kinase activity.
Negative_regulation (inhibition) of PARP-1
3) Confidence 0.58 Published 2007 Journal BMC Mol Biol Section Body Doc Link PMC1868035 Disease Relevance 0.32 Pain Relevance 0
Since inhibitors of the nuclear enzyme poly-(ADP-ribose) polymerase (PARP) were found to be beneficial in many pathophysiological conditions associated with oxidative stress and PARP-1 knock-out mice proved to be resistant to bacterial lipopolysaccharide (LPS)-induced septic shock, PARP inhibitors are candidates for such a role.
Negative_regulation (inhibitors) of PARP in poly associated with targeted disruption, stress and sepsis
4) Confidence 0.57 Published 2003 Journal Biochem. Pharmacol. Section Abstract Doc Link 12694878 Disease Relevance 0.76 Pain Relevance 0.20
PARP activity assay and administration of PARP inhibitor
Negative_regulation (inhibitor) of PARP
5) Confidence 0.56 Published 2008 Journal Crit Care Section Body Doc Link PMC2575597 Disease Relevance 0.50 Pain Relevance 0.10
Recently, Vaschetto and colleagues [29] reported the effect of PARP inhibitor in the rat model in which MV was performed after intratracheal LPS instillation.
Negative_regulation (inhibitor) of PARP
6) Confidence 0.56 Published 2008 Journal Crit Care Section Body Doc Link PMC2575597 Disease Relevance 1.51 Pain Relevance 0.08
It would be difficult to determine whether PARP is activated by LPS, injurious MV setting, or both and whether the PARP inhibitor exerts its effect by inhibition of PARP from LPS, injurious MV setting, or both.
Spec (whether) Negative_regulation (inhibition) of PARP
7) Confidence 0.56 Published 2008 Journal Crit Care Section Body Doc Link PMC2575597 Disease Relevance 0.94 Pain Relevance 0.03
Despite the absence of direct measurement of peroxynitrite in this experiment, the increased level of the NOX due to injurious MV could yield peroxynitrite by reaction with increased ROS, along with PARP activity, and inhibition of PARP reduced MPO activity and NOX level.
Negative_regulation (inhibition) of PARP associated with urological neuroanatomy
8) Confidence 0.56 Published 2008 Journal Crit Care Section Body Doc Link PMC2575597 Disease Relevance 0.87 Pain Relevance 0.20
It would be difficult to determine whether PARP is activated by LPS, injurious MV setting, or both and whether the PARP inhibitor exerts its effect by inhibition of PARP from LPS, injurious MV setting, or both.
Spec (whether) Negative_regulation (inhibitor) of PARP
9) Confidence 0.56 Published 2008 Journal Crit Care Section Body Doc Link PMC2575597 Disease Relevance 0.94 Pain Relevance 0.03
Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.
Negative_regulation (inhibition) of PARP associated with paracetamol and hepatitis
10) Confidence 0.52 Published 1996 Journal Gen. Pharmacol. Section Abstract Doc Link 8742498 Disease Relevance 0.59 Pain Relevance 0.88
Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.
Negative_regulation (inhibitor) of PARP in liver associated with paracetamol, injury and hepatitis
11) Confidence 0.52 Published 1996 Journal Gen. Pharmacol. Section Abstract Doc Link 8742498 Disease Relevance 0.41 Pain Relevance 0.56
Thus, a markedly immunohistochemical staining of PARP was detected in sections of pancreas, lung and gut from zymosan-treated mice, while, here, we have observed a decrease of PARP activity in samples of mice treated with GW0742.
Negative_regulation (decrease) of PARP in gut
12) Confidence 0.50 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2844385 Disease Relevance 0.71 Pain Relevance 0.08
Clinical trials to assess the toxicity and potential benefit of combining radiotherapy with PARP inhibition are now needed.
Negative_regulation (inhibition) of PARP associated with toxicity
13) Confidence 0.43 Published 2010 Journal Cancer Treat. Rev. Section Abstract Doc Link 20409643 Disease Relevance 0.73 Pain Relevance 0.06
Pre-clinical data suggest that PARP inhibitors may potentiate the effects of radiotherapy in several tumour types, namely lung, colorectal, head and neck, glioma, cervix and prostate cancers.
Negative_regulation (inhibitors) of PARP in neck associated with cancer, prostate cancer and glioma
14) Confidence 0.43 Published 2010 Journal Cancer Treat. Rev. Section Abstract Doc Link 20409643 Disease Relevance 0.69 Pain Relevance 0.08
The protection of 3-aminobenzamide against AAP-induced liver injury was due to reduced metabolic activation and potentially its antioxidant effect but independent of PARP-1 inhibition.
Negative_regulation (inhibition) of PARP-1 in liver associated with paracetamol and injury
15) Confidence 0.43 Published 2005 Journal Toxicol. Sci. Section Abstract Doc Link 15601672 Disease Relevance 0.59 Pain Relevance 0.55
The results support a rationale for the development of potent and low-toxicity PARP inhibitors and PARP inhibitor-containing combination therapies.
Negative_regulation (inhibitors) of PARP associated with toxicity
16) Confidence 0.43 Published 2008 Journal Free Radic. Biol. Med. Section Abstract Doc Link 17976390 Disease Relevance 1.00 Pain Relevance 0.40
The results support a rationale for the development of potent and low-toxicity PARP inhibitors and PARP inhibitor-containing combination therapies.
Negative_regulation (inhibitors) of PARP associated with toxicity
17) Confidence 0.43 Published 2008 Journal Free Radic. Biol. Med. Section Abstract Doc Link 17976390 Disease Relevance 1.00 Pain Relevance 0.40
Inhibition of PARP also induces DNA double strand breaks which were dependent on the presence of ATM.
Negative_regulation (Inhibition) of PARP
18) Confidence 0.43 Published 2007 Journal BMC Mol Biol Section Abstract Doc Link PMC1868035 Disease Relevance 0 Pain Relevance 0
In summary our results show that while PARP-1 is needed in the response of ATM to gamma irradiation, the inhibition of PARP induces DNA double strand breaks (which are resolved in and ATM-dependent pathway) and activates ATM kinase.



Negative_regulation (inhibition) of PARP
19) Confidence 0.43 Published 2007 Journal BMC Mol Biol Section Abstract Doc Link PMC1868035 Disease Relevance 0 Pain Relevance 0
Therefore the question still remains open as to how human tumors could benefit from PARP inhibition during radiotherapy.
Negative_regulation (inhibition) of PARP associated with cancer
20) Confidence 0.43 Published 2007 Journal BMC Mol Biol Section Body Doc Link PMC1868035 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox